94 related articles for article (PubMed ID: 24956248)
1. Polymorphisms in translesion polymerase genes influence treatment outcome in malignant mesothelioma.
Goričar K; Kovač V; Dolžan V
Pharmacogenomics; 2014 May; 15(7):941-50. PubMed ID: 24956248
[TBL] [Abstract][Full Text] [Related]
2. Translesion polymerase genes polymorphisms and haplotypes influence survival of osteosarcoma patients.
Goričar K; Kovač V; Jazbec J; Zakotnik B; Lamovec J; Dolžan V
OMICS; 2015 Mar; 19(3):180-5. PubMed ID: 25748439
[TBL] [Abstract][Full Text] [Related]
3. Genetic polymorphisms in aquaporin 1 as risk factors for malignant mesothelioma and biomarkers of response to cisplatin treatment.
Senk B; Goricar K; Kovac V; Dolzan V; Franko A
Radiol Oncol; 2019 Mar; 53(1):96-104. PubMed ID: 30840592
[TBL] [Abstract][Full Text] [Related]
4. REV3L 3'UTR 460 T>C polymorphism in microRNA target sites contributes to lung cancer susceptibility.
Zhang S; Chen H; Zhao X; Cao J; Tong J; Lu J; Wu W; Shen H; Wei Q; Lu D
Oncogene; 2013 Jan; 32(2):242-50. PubMed ID: 22349819
[TBL] [Abstract][Full Text] [Related]
5. REV3L single nucleotide variants lead to increased susceptibility towards non-small cell lung cancer in the population of Jammu and Kashmir.
Jamwal RS; Mahajan N; Bhat GR; Bhat A; Shah R; Verma S; Sharma M; Sharma B; Qadri RA; Kumar R; Bhat A
Cancer Epidemiol; 2021 Dec; 75():102047. PubMed ID: 34655923
[TBL] [Abstract][Full Text] [Related]
6. Genetic variation in genes encoding for polymerase ζ subunits associates with breast cancer risk, tumour characteristics and survival.
Varadi V; Bevier M; Grzybowska E; Johansson R; Enquist K; Henriksson R; Butkiewicz D; Pamula-Pilat J; Tecza K; Hemminki K; Lenner P; Försti A
Breast Cancer Res Treat; 2011 Aug; 129(1):235-45. PubMed ID: 21455670
[TBL] [Abstract][Full Text] [Related]
7. The influence of platinum pathway polymorphisms on the outcome in patients with malignant mesothelioma.
Erčulj N; Kovač V; Hmeljak J; Dolžan V
Ann Oncol; 2012 Apr; 23(4):961-7. PubMed ID: 21765044
[TBL] [Abstract][Full Text] [Related]
8. Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in.
Nowak AK; Lesterhuis WJ; Kok PS; Brown C; Hughes BG; Karikios DJ; John T; Kao SC; Leslie C; Cook AM; Pavlakis N; Briscoe K; O'Byrne KJ; Karapetis CS; Lam WS; Langford A; Yip S; Stockler MR
Lancet Oncol; 2020 Sep; 21(9):1213-1223. PubMed ID: 32888453
[TBL] [Abstract][Full Text] [Related]
9. Translesion synthesis mechanisms depend on the nature of DNA damage in UV-irradiated human cells.
Quinet A; Martins DJ; Vessoni AT; Biard D; Sarasin A; Stary A; Menck CF
Nucleic Acids Res; 2016 Jul; 44(12):5717-31. PubMed ID: 27095204
[TBL] [Abstract][Full Text] [Related]
10. The influence of genetic variability of DNA repair mechanisms on the risk of malignant mesothelioma.
Levpuscek K; Goricar K; Kovac V; Dolzan V; Franko A
Radiol Oncol; 2019 Mar; 53(2):206-212. PubMed ID: 30893058
[TBL] [Abstract][Full Text] [Related]
11. Genome Evolution Analysis of Recurrent Testicular Malignant Mesothelioma by Whole-Genome Sequencing.
Zhang S; Zhang Q; Sun Q; Tang J; Chen J; Ji N; Zheng Y; Fang F; Lei W; Li P; Zhang N
Cell Physiol Biochem; 2018; 45(1):163-174. PubMed ID: 29334678
[TBL] [Abstract][Full Text] [Related]
12. REV3L modulates cisplatin sensitivity of non-small cell lung cancer H1299 cells.
Wang W; Sheng W; Yu C; Cao J; Zhou J; Wu J; Zhang H; Zhang S
Oncol Rep; 2015 Sep; 34(3):1460-8. PubMed ID: 26165320
[TBL] [Abstract][Full Text] [Related]
13. First-line chemotherapy with pemetrexed plus cisplatin for malignant peritoneal mesothelioma.
Fujimoto E; Kijima T; Kuribayashi K; Negi Y; Kanemura S; Mikami K; Doi H; Kitajima K; Nakano T
Expert Rev Anticancer Ther; 2017 Sep; 17(9):865-872. PubMed ID: 28594258
[TBL] [Abstract][Full Text] [Related]
14. Matrix Metalloproteinases Polymorphisms as Prognostic Biomarkers in Malignant Pleural Mesothelioma.
Štrbac D; Goričar K; Dolžan V; Kovač V
Dis Markers; 2017; 2017():8069529. PubMed ID: 29138529
[TBL] [Abstract][Full Text] [Related]
15. Association of two BRM promoter polymorphisms and smoking status with malignant pleural mesothelioma risk and prognosis.
Lee MJ; Kuehne N; Hueniken K; Liang S; Rai S; Sorotsky H; Herman M; Shepshelovich D; Bruce J; Liang M; Patel D; Cheng D; Chen Z; Eng L; Brown MC; Cho J; Leighl NB; de Perrot M; Reisman D; Xu W; Bradbury PA; Liu G
Mol Carcinog; 2019 Nov; 58(11):1960-1973. PubMed ID: 31355511
[TBL] [Abstract][Full Text] [Related]
16. High RRM1 Expression Is Associated with Adverse Outcome in Patients with Cisplatin/Vinorelbine-treated Malignant Pleural Mesothelioma.
Zimling ZG; Santoni-Rugiu E; Bech C; Sørensen JB
Anticancer Res; 2015 Dec; 35(12):6731-8. PubMed ID: 26637889
[TBL] [Abstract][Full Text] [Related]
17. Absence of REV3L promotes p53-regulated cancer cell metabolism in cisplatin-treated lung carcinoma cells.
Kong L; Murata MM; Digman MA
Biochem Biophys Res Commun; 2018 Jan; 496(1):199-204. PubMed ID: 29307819
[TBL] [Abstract][Full Text] [Related]
18. ERCC1, MLH1, MSH2, MSH6, and βIII-tubulin: resistance proteins associated with response and outcome to platinum-based chemotherapy in malignant pleural mesothelioma.
Ting S; Mairinger FD; Hager T; Welter S; Eberhardt WE; Wohlschlaeger J; Schmid KW; Christoph DC
Clin Lung Cancer; 2013 Sep; 14(5):558-567.e3. PubMed ID: 23810210
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma.
Krug LM; Wozniak AJ; Kindler HL; Feld R; Koczywas M; Morero JL; Rodriguez CP; Ross HJ; Bauman JE; Orlov SV; Ruckdeschel JC; Mita AC; Fein L; He X; Hall R; Kawabe T; Sharma S
Lung Cancer; 2014 Sep; 85(3):429-34. PubMed ID: 25047675
[TBL] [Abstract][Full Text] [Related]
20. A Randomized Phase II Study Adding Axitinib to Pemetrexed-Cisplatin in Patients with Malignant Pleural Mesothelioma: A Single-Center Trial Combining Clinical and Translational Outcomes.
Buikhuisen WA; Scharpfenecker M; Griffioen AW; Korse CM; van Tinteren H; Baas P
J Thorac Oncol; 2016 May; 11(5):758-768. PubMed ID: 26845191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
